Article
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.
Lung cancer (Amsterdam, Netherlands) - 1 Dec 2006
Asahina Hajime, Yamazaki Koichi, Kinoshita Ichiro, Yokouchi Hiroshi, Dosaka-Akita Hirotoshi, Nishimura Masaharu
Abstract excerpt
Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) are associated with clinical responsiveness to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancers (NSCLCs). However, certain rare EGFR mutations including S768I are re...
Topics
- Adenocarcinoma
- DNA, Neoplasm
- Drug Resistance, Neoplasm
- ErbB Receptors
- Gefitinib
- Humans
- Isoleucine
- Leucine
- Lung Neoplasms
- Male
- Middle Aged
- Mutation
- Quinazolines
- Serine
- Valine